The American Cancer Society’s impact investment fund, BrightEdge LLC, today named its first Founder’s Circle members, securing contributions totaling $2.5 million. Launched with an initial $25 million investment from the American Cancer Society (ACS), the mission-driven fund invests in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies. The impact investment donations are BrightEdge’s first since its formation.
BrightEdge is the American Cancer Society’s donor-funded impact venture capital fund. The fund invests in for-profit companies that are developing therapeutics, diagnostics, medical devices, and technologies to eradicate cancer in ways aligned with the American Cancer Society’s impact pillars. It seeks to invest alongside top-tier life sciences and healthcare investors with a goal of generating financial returns over a four- to seven-year timeframe. Returns are generated when a portfolio company either goes public or is acquired by a strategic investor. Read more.
